The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.
| Level | Code | Title | |
|---|---|---|---|
| 1 | L | Antineoplastic and immunomodulating agents | |
| 2 | L01 | Antineoplastic agents | |
| 3 | L01E | Protein kinase inhibitors | |
| 4 | L01EL | Bruton's tyrosine kinase (BTK) inhibitors | |
| 5 | L01EL02 |
| Active Ingredient | Description | |
|---|---|---|
| Acalabrutinib |
Acalabrutinib is a small-molecule inhibitor of BTK (Bruton’s tyrosine kinase). Acalabrutinib and its active metabolite, ACP-5862, form a covalent bond with a cysteine residue in the BTK active site, leading to inhibition of BTK enzymatic activity. In nonclinical studies, acalabrutinib inhibited BTK-mediated activation of downstream signaling proteins CD86 and CD69 and inhibited malignant B-cell proliferation and tumor growth in mouse xenograft models. |
| Title | Information Source | Document Type | |
|---|---|---|---|
| CALQUENCE Capsule | FDA, National Drug Code (US) | MPI, US: SPL/PLR | |
| CALQUENCE Film-coated tablet | European Medicines Agency (EU) | MPI, EU: SmPC | |
| CALQUENCE Hard capsule | European Medicines Agency (EU) | MPI, EU: SmPC |
Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.
